Trial Profile
Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2019
Price :
$35
*
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms BELACOR
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 23 Dec 2018 Results assessing belatacept in renal transplant recipient compared to ancillary control group, published in the American Journal of Transplantation.
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress